NYSE · Pharmaceutical Preparations
pharmaceutical company
81 entities across 48 jurisdictions, 4 in offshore financial centres. Read directly from the company’s own 10-K EX-21 filed 2026-02-24 — see the exhibit.
Which other public companies file entities in the same places:
| Entity | Jurisdiction | Note |
|---|---|---|
| Organon Argentina S.R.L. | Argentina | |
| Organon Pharma Pty Ltd | Australia | |
| Organon Austria GmbH | Austria | |
| Organon Belgium BV | Belgium | |
| Organon Heist BV | Belgium | |
| Dermavant Sciences Ltd. | Bermuda | offshore centre |
| Organon Farmacêutica Ltda. | Brazil | |
| Organon Canada Inc. | Canada | |
| Organon Chile SpA | Chile | |
| Organon Colombia S.A.S. | Colombia | |
| Organon Czech Republic s.r.o. | Czech Republic | |
| Organon Denmark ApS | Denmark | |
| Organon Pharmaceutical Egypt LLC | Egypt | |
| Organon R&D Finland Oy | Finland | |
| Organon Finland Oy | Finland | |
| Organon France SAS | France | |
| Organon Healthcare GmbH | Germany | |
| Organon Hungary Korlatolt Felelossegu Tarsasag | Hungary | |
| Fulford (India) Private Limited | India | |
| Organon (India) Private Limited | India | |
| PT Organon Pharma Indonesia Tbk | Indonesia | |
| Dermavant Sciences IRL Limited | Ireland | |
| Organon (Ireland) Ltd | Ireland | |
| Organon Pharma (Ireland) Limited | Ireland | |
| Organon Pharma Israel Ltd. | Israel | |
| Organon Italia S.r.l. | Italy | |
| Organon K.K. | Japan | |
| Organon Malaysia Sdn. Bhd. | Malaysia | |
| Organon Comercializadora, S. de R.L. de C.V. | Mexico | |
| Productos Farmaceuticos Organon Mexicana S. de R.L. de C.V. | Mexico | |
| Organon Pharma Mexico, S.A. de C.V. | Mexico | |
| Servicios Organon S. de R.L. de C.V. | Mexico | |
| Undra, S.A. de C.V. | Mexico | |
| Organon Maroc S.A.R.L. | Morocco | |
| GTS FI B.V. | Netherlands | |
| N.V. Organon | Netherlands | |
| OBS Human Health Holding B.V. | Netherlands | |
| OBS International 9 B.V. | Netherlands | |
| Organon Mexico Holdings B.V. | Netherlands | |
| Organon (I.A.) B.V. | Netherlands | |
| Organon Asia Holdings B.V. | Netherlands | |
| Organon Foreign Debt Co-Issuer B.V. | Netherlands | |
| Organon Holdings 9 B.V. | Netherlands | |
| Organon International Holdings 9 B.V. | Netherlands | |
| Organon Participations B.V. | Netherlands | |
| Organon Pharma B.V. | Netherlands | |
| Organon New Zealand Limited | New Zealand | |
| Organon Norway A/S | Norway | |
| Organon Pharma S. de R.L. | Panama | offshore centre |
| Organon BioSciences Peru S.R.L. | Peru | |
| Organon Polska Sp. z.o.o. | Poland | |
| Organon Global Shared Services Center (GSS), Unipessoal Lda. | Portugal | |
| Organon Portugal, Sociedade Unipessoal Lda. | Portugal | |
| Organon Puerto Rico LLC | Puerto Rico | |
| Organon BioSciences S.R.L. | Romania | |
| Organon Asia Pacific Services Pte. Ltd. | Singapore | |
| Organon Singapore Pte. Ltd. | Singapore | |
| Organon South Africa Pty Ltd. | South Africa | |
| Organon Salud, S.L. | Spain | |
| Organon Sweden AB | Sweden | |
| Dermavant Sciences GmbH | Switzerland | |
| Organon Central East GmbH | Switzerland | |
| Organon GmbH | Switzerland | |
| Organon International GmbH | Switzerland | |
| Organon International Services GmbH | Switzerland | |
| Organon KSA GmbH | Switzerland | |
| Organon (Thailand) Ltd. | Thailand | |
| Organon Turkey Ilaclari Limited Sirketi | Turkey | |
| Organon Ukraine Limited Liability Company | Ukraine | |
| Organon Pharma FZ-LLC | United Arab Emirates | |
| Dashtag | United Kingdom | |
| Dermavant Holdings Limited | United Kingdom | |
| Organon Pharma (UK) Limited | United Kingdom | |
| Organon Limited Liability Company | Vietnam | |
| Organon Pharma B.V. - Cyprus Branch | Cyprus | offshore centre |
| Organon Central East GmbH Scientific Office | Egypt | |
| Organon Belgium BV - Luxembourg Branch | Luxembourg | offshore centre |
| Organon KSA GmbH - Saudi Scientific Office | Saudi Arabia | |
| The Representative Office of Organon Central East GmbH in Ho Chi Minh City | Vietnam | |
| The Representative Office of Organon Central East GmbH in Hanoi | Vietnam | |
| The Representative Office of Organon Hong Kong Limited in Hanoi | Vietnam |
Two standard screens, computed from the XBRL in FY2025 against FY2024. Every test shows the numbers behind it — a score with its inputs hidden is a number you cannot check.
| Year | Revenue | Net income | Free cash flow | Gross margin | Shares |
|---|---|---|---|---|---|
| FY2020 | $6.5B | $2.2B | $2.0B | — | 253,516,000 |
| FY2021 | $6.3B | $1.4B | $2.0B | — | 254,192,700 |
| FY2022 | $6.2B | $917.0M | $662.0M | 62.8% | 255,169,000 |
| FY2023 | $6.3B | $1.0B | $548.0M | 59.8% | 256,270,000 |
| FY2024 | $6.4B | $864.0M | $764.0M | 58.0% | 259,152,000 |
| FY2025 | $6.2B | $187.0M | $538.0M | 53.3% | 260,764,000 |
11 institutions tracked — 4 added, 6 reduced, 1 opened a new position, 3 sold out. Index money added 98,708 shares while active managers cut 6,780,317.
| Manager | Kind | Shares | Change | Value |
|---|---|---|---|---|
| AQR CAPITAL MANAGEMENT LLC | Hedge fund | 1,245,588 | −2,205,038 | $16.8M |
| CITADEL ADVISORS LLC | Hedge fund | 846,659 | −2,083,431 | $11.5M |
| FMR LLC | Active fund | 1,187,549 | −1,371,143 | $16.1M |
| MORGAN STANLEY | Active fund | 2,202,199 | −1,090,485 | $29.8M |
| BlackRock, Inc. | Index | 32,056,866 | +339,838 | $434.0M |
| STATE STREET CORP | Index | 9,659,371 | −297,403 | $130.8M |
| BANK OF AMERICA CORP /DE/ | Active fund | 649,755 | −88,747 | $8.8M |
| GEODE CAPITAL MANAGEMENT, LLC | Index | 4,815,610 | +56,273 | $65.2M |
| PRICE T ROWE ASSOCIATES INC /MD/ | Active fund | 239,671 | +38,539 | $3.2M |
| JPMORGAN CHASE & CO | Active fund | 318,314 | +19,988 | $4.5M |
NORGES BANK holds a position with no prior filing to compare against, so its change is unknown rather than zero — and it is left out of the totals above.
From 13F filings, which cover institutions managing over $100m and are filed up to 45 days after the quarter ends — so this is a considered position, not a live one, and it is not the whole shareholder register.
What the company actually paid out and bought back, as reported — the record behind any yield figure.
Ownership percentages are a vendor aggregate, not a filing — unlike everything else on this page.
Organon & Co. files under SIC 2834 — all 50 pharmaceutical preparations companies compared on assets and F-score.
The structure map above is the Corporate Blueprint, and in the desktop it is interactive — click any entity to re-centre the map on it and walk the ownership chain. It sits alongside the screener, the scorecard and the filings lab on one desk, on your machine.
Sourced from SEC EDGAR primary filings. Figures are as reported by the company and are not investment advice. Scores are standard published screens computed from those filings; every input is shown above so you can check the arithmetic.
